Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, which are infection and tumor-fighting white blood cells, so that they have a ...

After years of type 2 diabetes, red blood cells can turn from harmless to harmful, damaging blood vessels and raising the risk of heart disease. Scientists say a molecule called microRNA-210 could ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

Researchers discovered a way to keep T cells from wearing out during the fight against cancer, and the approach could make immune-based treatments far more powerful. They found that tumors use a ...

Cabaletta Bio’s CAR-T cell therapy has eliminated the overreactive B cells of two patients with an autoimmune disease without preconditioning chemotherapy, pleasing investors and analysts while ...

DuoCAR20.19.22-D95 targets CD19, CD20, and CD22, addressing antigen escape in B-cell malignancies like B-ALL and B-NHL. Early-stage trials show no safety concerns for DuoCAR20.19.22-D95, with ongoing ...

Dinosaur DNA remains out of reach, so scientists hunt rarer clues: soft tissues entombed in bone. Using synchrotron X-rays, researchers visualized iron-rich casts of blood vessels inside a healing T.

Aims: to clarify the endoplasmic reticulum stress (ERS) status of CD4+ T lymphocytes in sepsis patients, particularly elderly individuals aged over 65 years, and to elucidate its association with mTOR ...

Sarah Bird is at the Institute of Cancer Research, London SM2 5NG, UK and at the Royal Marsden Hospital NHS Foundation Trust, London. Charlotte Pawlyn is at the Institute of Cancer Research, London ...

Work described in this story was made possible in part by federal funding supported by taxpayers. At Harvard Medical School, the future of efforts like this — done in service to humanity — now hangs ...